Effects of imidazole-2-hydroxibenzoate on glycosaminoglycan and albumin urinary excretion in type 1 diabetic patients.
The effect of imidazole-2-hydroxibenzoate on urinary excretion rates of glycosaminoglycans and albumin in 22 insulin-dependent diabetics with albumin excretion rates under 300 mg/day was evaluated in a 165-day double blind crossover study. Unlike placebo, the drug reduced glycosaminoglycan and albumin excretion rates significantly after 40 and 60 days of treatment, and the effects were significantly intercorrelated. Moreover, a parallel reduction in urinary excretion of N-acetyl-beta-D-glucosaminidase was also observed. These pharmacological effects may have a positive impact on the subsequent natural history of diabetic nephropathy.
Baggio
B
B
Institute of Internal Medicine, University of Padova, Italy.
Briani
G
G
Cicerello
E
E
Gambaro
G
G
Giorato
C
C
Iori
E
E
Lavagnini
T
T
Crepaldi
G
G
D000118:Acetylglucosaminidase / Q000652:urine; D000293:Adolescent; D000328:Adult; D000419:Albuminuria; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D003922:Diabetes Mellitus, Type 1 / Q000652:urine*; D005260:Female; D006025:Glycosaminoglycans / Q000652:urine*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D012459:Salicylates / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006025:Glycosaminoglycans; D007093:Imidazoles; D012459:Salicylates; C043292:imidazole-2-hydroxybenzoate; D000118:Acetylglucosaminidase